Abstract

Due to the strong heterogeneity of bladder cancer (BC), there is often substantial variation in the prognosis and efficiency of immunotherapy among BC patients. For the precision treatment and assessment of prognosis, the subtyping of BC plays a critical role. Despite various subtyping methods proposed previously, most of them are based on a limited number of molecules, and none of them is developed on the basis of cell states. In this study, we construct a single-cell atlas by integrating single cell RNA-seq, RNA microarray, and bulk RNA-seq data to identify the absolute proportion of 22 different cell states in BC, including immune and nonimmune cell states derived from tumor tissues. To explore the heterogeneity of BC, BC was identified into four different subtypes in multiple cohorts using an improved consensus clustering algorithm based on cell states. Among the four subtypes, C1 had median prognosis and best overall response rate (ORR), which characterized an immunosuppressive tumor microenvironment. C2 was enriched in epithelial-mesenchymal transition/invasion, angiogenesis, immunosuppression, and immune exhaustion. Surely, C2 performed the worst in prognosis and ORR. C3 with worse ORR than C2 was enriched in angiogenesis and almost nonimmune exhaustion. Displaying an immune effective environment, C4 performed the best in prognosis and ORR. We found that patients with just an immunosuppressive environment are suitable for immunotherapy, but patients with an immunosuppressive environment accompanied by immune exhaustion or angiogenesis may resist immunotherapy. Furthermore, we conducted exploration into the heterogeneity of the transcriptome, mutational profiles, and somatic copy-number alterations in four subtypes, which could explain the significant differences related to cell states in prognosis and ORR. We also found that PD-1 in immune and tumor cells could both influence ORR in BC. The level of TGFβ in a cell state can be opposite to the overall level in the tissues, and the level in a specific cell state could predict ORR more accurately. Thus, our work furthers the understanding of heterogeneity and immunotherapy resistance in BC, which is expected to assist clinical practice and serve as a supplement to the current subtyping method from a novel perspective of cell states.

Highlights

  • Around the world, there were a total of 5,73,278 new cases and 2,12,536 new deaths linked to bladder cancer (BC) in 2020 (Sung et al, 2021)

  • The macrophage was subclustered into M1_macrophage and M2_macrophage; DC was subclustered into pDC, cDC1, and cDC2; NK was subclustered into Natural_killer_CD56bright and Natural_killer_CD56dim; and fibroblasts were subclustered into myCAF and iCAF based on the Cellmarker database (Figure 1B)

  • The markers of each cell state were identified by Seurat (Supplementary Table S1), and the top two markers of each cell state were displayed by heatmap (Figure 1C)

Read more

Summary

Introduction

There were a total of 5,73,278 new cases and 2,12,536 new deaths linked to bladder cancer (BC) in 2020 (Sung et al, 2021). Some patients even showed intolerance to the toxicity of platinum-based chemotherapy, rendering the prognosis of BC relatively poor. The emergence of immunotherapy has made immune checkpoint blockades applicable to BC patients, especially those with intolerance to platinum-based chemotherapy. There have been five immune checkpoint inhibitors approved for metastatic BC and adopted as the standard second-line treatment for BC after the failure of platinum-based chemotherapy. Discovering the relationship between the heterogeneity of TME and immunotherapy resistance against BC and identifying those patients fit for immunotherapy remain arduous tasks. To solve this problem and obtain a deeper understanding of heterogeneity in BC, there are various subtyping methods proposed. TCGA-BLCA defined five subtypes, including luminal, luminal_infiltrated, luminal_papillary, basal_squamous, and neuronal; the basal subtype is usually associated with a bad prognosis, whereas luminal_papillary is associated with a good prognosis (Robertson et al, 2017)

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.